Webinars, Pharmaceutical

Aptar Pharma discusses intranasal administration for CNS therapeutics

CNS therapies are a well-defined target for drug repurposing for intranasal administration with a growing track record of success that includes commercialized products for treatment resistant depression and seizures.

This webinar examines the defining benefits of intranasal administration such as high patient acceptability, rapid onset, and the ability to deliver drugs to unconscious patients. The biology of drug delivery for CNS therapeutics is also explored with reference to the benefits of bypassing the blood brain barrier. Off-the-shelf devices for intranasal administration are reviewed and strategies for reformulation – powder or liquid – are considered.

The expert support available from Aptar Pharma, to support all aspects of drug reformulation for intranasal administration, are also discussed.

Watch the webinar
Speaker(s): Dr. Julie D. Suman
25 Feb 2022

Learn more about Aptar Pharma Expertise
in Nasal Drug Delivery

Find Out More

This Might Also Be of Interest

24 Apr 2024

Advancing OINDP Clinical Trials with Speed and Efficiency: Strategies for Success

Publications, Pharmaceutical, Product Solutions, Innovation & Insights, Market Insights

Read More
24 Apr 2024

Exploring Nasal Casts in Nasal Drug Development

Publications, Pharmaceutical, Market Insights, Product Solutions, Innovation & Insights

Read More
3 Apr 2024

Delivering Nasally Administered Biologics

Webinars, Pharmaceutical, Market Insights, Product Solutions, Innovation & Insights, Device Innovations

Read More
3 Apr 2024

Nasal Casts, Tools to Enable Nasal Drug Delivery Development

Webinars, Pharmaceutical, Device Innovations, Market Insights, Product Solutions

Read More
1 2 3 25

Request Access


Requesting access to Aptar Pharma discusses intranasal administration for CNS therapeutics.

  • This field is for validation purposes and should be left unchanged.
Back To Top